Targeted Therapies: Treatment Options for Patients With Metastatic Breast Cancer

Rachel Richards

Elizabeth Keating

Jean E. Boucher

breast cancer, hormone epidermal growth factor, targeted therapy
CJON 2019, 23(4), 434-438. DOI: 10.1188/19.CJON.434-438

Standard therapies for treating hormone-sensitive metastatic breast cancer (BC) include the blockage of estrogen pathways by using selective estrogen modulator receptors or selective estrogen receptor downregulators and by using aromatase inhibitors to block estrogen production. The addition of nonhormonal targeted therapies, including therapies based on alternative molecular pathways, continues to expand rapidly for advanced or metastatic BC. This article reviews targeted therapy treatment options for patients with metastatic BC, including strategies for administration, side effects, and nursing considerations.


  • Targeted therapies for the treatment of metastatic BC are based on inhibition of different molecular pathways and mutations.
  • The number of metastatic BC therapies, including oral anticancer agents, that can be self-administered by patients at home are increasing.
  • Oncology nurses who are familiar with evolving metastatic BC therapies are best equipped to provide comprehensive patient care and support.
Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.